ETTX
Entasis Therapeutics Holdings Inc.
Set alert
2.19 0.00 0.00%
2.19 Day range 2.20
52-week range unavailable
- Open
- 2.19
- Prev close
- 2.19
- Mkt cap
- 0
- Vol
- 0
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 2.19
- High
- 2.20
- Forward P/E
- 0.00
- Beta
- 0.00
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 10, 2022
- 50-d avg
- 0.00
- 200-d avg
- 0.00
- 1y target
- 2.00
Key statistics
- Market cap
- 0
- Trailing P/E
- 0.00
- Forward P/E
- 0.00
- Price / sales
- 0.00
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 0
- Total debt
- 0
- Return on equity
- 0.00%
- 50-day average
- 0.00
- 200-day average
- 0.00
Analyst view
Consensus: hold
Hold
Price target (mean) 2.00
Ratings (0m) 3 3 buy · 0 hold · 0 sell
- Strong buy1
- Buy2
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 10, 2022
Expected Aug 10, 2022. Consensus EPS estimate -0.29.
Financials — quick view
ETTX Revenue — quarterly 0
ETTX Net income — quarterly -15.26M
ETTX EPS — quarterly -0.32
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 10, 2022 | Jun 1, 2022 | -0.28 | — | — | — |
| Apr 27, 2022 | Mar 1, 2022 | -0.20 | — | — | — |
| Mar 3, 2022 | Dec 1, 2021 | -0.26 | — | — | — |
| Nov 4, 2021 | Sep 1, 2021 | -0.26 | — | — | — |
| Aug 11, 2021 | Jun 1, 2021 | -0.24 | — | — | — |
| May 5, 2021 | Mar 1, 2021 | -0.34 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| May 5, 2022 | Cantor Fitzgerald | down | Overweight | Neutral |
| Mar 15, 2022 | Alliance Global Partners | down | Buy | Neutral |
| Mar 7, 2022 | Wedbush | down | Outperform | Neutral |
| Mar 3, 2022 | HC Wainwright & Co. | down | Buy | Neutral |
| Oct 19, 2021 | BMO Capital | main | — | Outperform |
| Oct 18, 2021 | HC Wainwright & Co. | main | — | Buy |
News
- Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO® (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China
- Innoviva Announces Expiration of Cash Tender Offer for Shares of Entasis Therapeutics Holdings Inc.
- Innoviva Announces Expiration of Cash Tender Offer for Shares of Entasis Therapeutics Holdings Inc.
- Scott+Scott Attorneys at Law LLP Investigates Innoviva Buyout of Entasis – ETTX
- Scott+Scott Attorneys at Law LLP Investigates Innoviva Buyout of Entasis – ETTX
- ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Entasis Therapeutics Holdings Inc.
- Entasis (ETTX) Stock Rises on Buyout Offer From Innoviva
- ENTASIS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Entasis Therapeutics Holdings Inc. - ETTX
- ETTX Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Entasis Therapeutics Holdings Inc. Is Fair to Shareholders
- Innoviva Acquires AstraZeneca-Spin Off At $2.20/Share
Your note
Sign in to keep a note on ETTX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BERGER HEATHER | Director | Stock Award(Grant) | Jan 17, 2022 | 49,500 |
| GUTCH MICHAEL PH.D. | Chief Financial Officer | Stock Award(Grant) | Jan 17, 2022 | 167,572 |
| HASTINGS DAVID C | Director | Stock Award(Grant) | Jan 17, 2022 | 49,500 |
| KEILEY ELIZABETH M | General Counsel | Stock Award(Grant) | Jan 17, 2022 | 167,572 |
| MAYER HOWARD | Director | Stock Award(Grant) | Jan 17, 2022 | 49,500 |
| MEEK DAVID D | Director | Stock Award(Grant) | Jan 17, 2022 | 49,500 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Tpg Group Holdings (sbs) Advisors, Inc. | 2.13% | 1,020,748 | 3.41M | Sep 29, 2021 |
| TPG GP A, LLC | 2.13% | 1,020,748 | 1.91M | Mar 30, 2022 |
| Eventide Asset Management LLC | 1.23% | 590,602 | 1.10M | Mar 30, 2022 |
| Vanguard Group, Inc. (The) | 1.01% | 483,723 | 904.56K | Mar 30, 2022 |
| Renaissance Technologies, LLC | 0.68% | 323,845 | 605.59K | Mar 30, 2022 |
| Bridgeway Capital Management, Inc. | 0.28% | 132,600 | 247.96K | Mar 30, 2022 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Mutual Fund Ser Tr-Eventide Gilead Fund | 1.23% | 590,602 | 1.10M | Mar 30, 2022 |
| Vanguard Total Stock Market Index Fund | 0.64% | 304,345 | 569.13K | Mar 30, 2022 |
| Vanguard Extended Market Index Fund | 0.36% | 173,140 | 323.77K | Mar 30, 2022 |
| Bridgeway Funds Inc-Ultra Small Company Market Fund | 0.28% | 132,600 | 247.96K | Mar 30, 2022 |
| Fidelity Extended Market Index Fund | 0.18% | 86,160 | 187.83K | May 30, 2022 |
| Fidelity NASDAQ Composite Index Fund | 0.07% | 32,026 | 69.82K | May 30, 2022 |